tiprankstipranks
Conmed (CNMD)
NYSE:CNMD
US Market
Want to see CNMD full AI Analyst Report?

Conmed (CNMD) Earnings Dates, Call Summary & Reports

205 Followers

Earnings Data

Report Date
Jul 29, 2026
After Close (Confirmed)
Period Ending
2026 (Q2)
Consensus EPS Forecast
1.11
Last Year’s EPS
1.15
Same Quarter Last Year
Based on 4 Analysts Ratings

Earnings Call Summary

Q1 2026
Earnings Call Date:Apr 29, 2026|
% Change Since:
|
Earnings Call Sentiment|Neutral
The call presented a mixed but constructive view: near‑term headwinds included modest revenue declines on a reported basis, lower adjusted net income and EPS, weaker cash from operations and higher working capital as inventory was intentionally built. Offsetting these concerns were upgraded organic revenue guidance (5.0%–6.5%), clear momentum in core growth platforms (AirSeal, Buffalo Filter direct smoke, BioBrace), improved gross margin (up 100 bps) and maintained full‑year adjusted EPS guidance despite a planned refinancing headwind. Management also completed GI divestitures to focus resources and continued buybacks. Overall the transcript shows cautious optimism with tangible operational and strategic progress balanced against short‑term financial pressures.
Company Guidance
CONMED raised its 2026 organic revenue growth outlook to 5.0%–6.5% (from 4.5%–6.0%), now expects reported revenue of $1.35B–$1.375B (Q2 revenue $336M–$340M), and reiterated adjusted EPS guidance of $4.30–$4.45 for the year while guiding Q2 adjusted EPS of $1.09–$1.14; foreign exchange is expected to be a 40–50 bps tailwind, AirSeal and direct smoke are still expected to grow in the high single-digit to low double‑digit range for the full year, and GI revenue for 2026 is now forecast at $14.5M–$17.5M (versus the prior $21M–$25M estimate, ~ $7M lower at the midpoint) with corresponding cost reductions; the company plans to refinance debt in Q2 with bank financing (eschewing new convertibles), which could increase full‑year adjusted interest expense and depress adjusted EPS by at least $0.10, yet operating cash flow is still forecast at $145M–$155M, capital expenditures $20M–$30M, free cash flow around $125M, and management expects to maintain ~3x leverage while continuing share repurchases (Q1 buybacks ~858k shares for $37.4M).
Raised Organic Revenue Guidance
Organic revenue guidance for FY2026 was raised to 5.0%–6.5% (from prior 4.5%–6.0%), with FX now expected to be a ~40–50 bps tailwind; reported 2026 revenue guidance increased at the low end to $1.35B–$1.375B and Q2 revenue is expected to be $336M–$340M.
Platform Momentum — Orthopedics and BioBrace
Orthopedics grew 4.5% worldwide in Q1 (U.S. +5.5%, international +3.9%); BioBrace showing strong adoption with >30 published studies and a 268‑patient RCT on track to complete enrollment in 2026 (publication expected 2027); orthopedics delivered its third consecutive quarter of at least mid‑single‑digit growth.
AirSeal Traction and Large TAM
AirSeal installed base exceeded 10,000 systems; continued Q1 growth with U.S. laparoscopic penetration only ~6%–7% of ~3 million annual procedures (indicating a large runway); management expects AirSeal to deliver high single‑digit to low double‑digit growth over the long term.
Buffalo Filter Growth Drivers and Regulatory Tailwind
Direct smoke evacuation grew in Q1 and remains a strategic focus; 20 U.S. states have smoke‑free OR laws covering ~51% of the population, providing legislative tailwinds; PlumeSafe X5 continues to gain traction in outpatient/ASC settings.
Improved Gross Margin
Adjusted gross margin in Q1 was 57.4%, improving 100 basis points year‑over‑year driven by favorable product mix and FX, and management reiterated a full‑year gross margin improvement target of 50–100 bps.
Capital Allocation Discipline — Buybacks and M&A Focus
Q1 share repurchases totaled ~858,000 shares for $37.4M; company re‑iterated priorities of organic investment, disciplined acquisitions aligned to platforms, and returning capital to shareholders while strengthening the balance sheet.
Strategic Portfolio Simplification and Supply Chain Progress
Completed divestitures of remaining GI product lines to sharpen focus on higher‑growth, higher‑margin platforms (GI revenue now expected $14.5M–$17.5M in 2026); supply chain performance improved with intentionally higher inventory to support service levels and allowed sales teams to go on offense.

Conmed (CNMD) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

CNMD Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Jul 29, 2026
2026 (Q2)
1.10 / -
1.15
Apr 29, 2026
2026 (Q1)
0.82 / 0.89
0.95-6.32% (-0.06)
Jan 28, 2026
2025 (Q4)
1.32 / 1.43
1.346.72% (+0.09)
Nov 05, 2025
2025 (Q3)
1.06 / 1.08
1.052.86% (+0.03)
Jul 30, 2025
2025 (Q2)
1.12 / 1.15
0.9817.35% (+0.17)
Apr 30, 2025
2025 (Q1)
0.81 / 0.95
0.7920.25% (+0.16)
Feb 05, 2025
2024 (Q4)
1.20 / 1.34
1.0626.42% (+0.28)
Oct 30, 2024
2024 (Q3)
1.02 / 1.05
0.916.67% (+0.15)
Jul 31, 2024
2024 (Q2)
0.91 / 0.98
0.8318.07% (+0.15)
Apr 24, 2024
2024 (Q1)
0.74 / 0.79
0.6619.70% (+0.13)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

CNMD Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Apr 29, 2026
$35.96$36.66+1.95%
Jan 28, 2026
$38.69$37.31-3.57%
Nov 05, 2025
$44.44$44.21-0.52%
Jul 30, 2025
$49.95$50.96+2.01%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Conmed (CNMD) report earnings?
Conmed (CNMD) is schdueled to report earning on Jul 29, 2026, After Close (Confirmed).
    What is Conmed (CNMD) earnings time?
    Conmed (CNMD) earnings time is at Jul 29, 2026, After Close (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is CNMD EPS forecast?
          CNMD EPS forecast for the fiscal quarter 2026 (Q2) is 1.11.